Cardiac REperfusion With Intralipid® at Reperfusion

Summary

This study will evaluate the benefit of Intralipid® or placebo administered prior to reperfusion to limit ischemia reperfusion injury as measured by the geometric mean difference of the release of troponin I over 72 hours after coronary artery bypass.

Timeline

Start

2017-01

Primary completion

2018-06

Completion

2018-06

Publications

• Hadebe N, Cour M, Imamdin A, Petersen T, Pennel T, Scherman J, Snowball J, Ntsekhe M, Zilla P, Swanevelder J, Lecour S. Cardioprotection with Intralipid During Coronary Artery Bypass Grafting Surgery on Cardiopulmonary Bypass: A Randomized Clinical Trial. Cardiovasc Drugs Ther. 2025 Oct;39(5):1045-1052. doi: 10.1007/s10557-024-07594-w. Epub 2024 Jun 12.

Drugs

Indications

No indication recorded.